期刊文献+

小剂量希罗达抗小鼠结肠癌生长及微血管的形成 被引量:1

Antiangiogneic Effect and Antitumor Effect of Minidose Xeloda on Mice with CT-26 Coloretical Carcinoma
下载PDF
导出
摘要 目的研究小剂量希罗达对小鼠结肠癌CT-26移植瘤生长和微血管生成的影响。方法建立小鼠结肠癌皮下移植瘤模型,随机分组:治疗组持续小剂量希罗达90mg/kg(每只0.1ml)灌胃,对照组给予相应体积生理盐水。给药后观察每组小鼠肿瘤生长情况,肿瘤长出后隔天测量肿瘤体积,接种肿瘤细胞两周后,处死全部小鼠,免疫组织化学法检测肿瘤组织血管内皮生长因子(VEGF)表达及肿瘤组织微血管密度(MVD),Western blot法检测肿瘤组织VEGF的表达。结果治疗组肿瘤生长受到明显抑制,治疗组VEGF表达强度及MVD低于对照组,VEGF与MVD间呈正相关;Western blot检测治疗组VEGF表达明显减弱。实验结束时未见明显不良反应。结论小剂量希罗达能通过抑制肿瘤微血管生成发挥抗肿瘤作用,其机制与抑制VEGF的表达有关。 Objective To evaluate the antiangiogenic effect and antitumor effect of the minidose Xeloda on the mice with coloretical carcinoma.Methods Sixteen Balbc mice modle with CT-26 coloretical carcinoma were established and randomized into two groups:Tested group (continues low dose Xeloda,90 mg/kg) and control group(0.9% sodium chloride).Then the size of tumor、weight of mice were observed.At the end of the experiment(2 weeks after modle making ),tumor tissue was given immunohistochemical staining. Tumor microvascular density (MVD) and vascular endothelial growth factor (VEGF) expression were detected, and VEGF expression was detected by Western blot. Results Compared with control group, tumor growth of tested group was obviously restrained. MVD and VEGF expression were decreased in tested group. There was no toxic reaction in tested group. Conclusion The continuous low dose of Xeloda played a role of antitumor by holding tumor vascularization. The possible mechanism is inhibiting the expression of VEGF.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2009年第12期1035-1038,共4页 Cancer Research on Prevention and Treatment
基金 云南省省院省校合作重点学科专项资金资助项目
关键词 希罗达 结肠肿瘤 血管生成 微血管密度 血管内皮生长因子 Xeloda Coloretical Carcinoma Vascularization MVD VEGF
  • 相关文献

参考文献11

  • 1I.oven D, Be'ery E, Yerushalmi R, el al. Daily low dose/con tinuous capecitabine combined with neo-akjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients [J]. Acta Oncol,2008,47(1 ) :104 -109.
  • 2Breasalier RS, Ho SB, Scheoppner HL, et al. Enhanced sialylation of mucin assioated carbohydrate structures in human colon cancer metastasis[J]. Gastroenterology, 1996, 110 (5): 1354- 1367.
  • 3Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma[J]. N Engl J Med, 1991,324(1 ) : 1-8.
  • 4Folkman J. Tumor angiogenesis: therapeutic implication[J]. N Engl J Med, 1971,285 (21 ) :1182-1186.
  • 5Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? [J]. Am J Pathol ,1998,153(1) :11-16.
  • 6Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during emhryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth[J]. Proc Natl Aead Sci USA, 1993,90 (19) :8915-8919.
  • 7Veikkola T, Karkkainen M, Claesson Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor re ceptors[J]. Cancer Res, 2000,60(2) :203-212.
  • 8KamatAA,KimTJ, Landen CNJr,et al. Metronomic chemotherapy enhances the efficacy of antivaascular therapy in ovari an cancer[J]. Cancer Res,2007,67(1):281-288.
  • 9Kerbel RS, Klement G, Pritchard kl, et al. Continuous lowdose anti-angiogenic/metronomie chemotherapy: from the research laboratory into the oncology clinic [J]. Ann Oncol, 2002,13(1) :12-15.
  • 10Steinbild S, Arends J, Medinger M,et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase Ⅱ study [J]. Onkologie, 2007,30(12) :629-635.

二级参考文献5

共引文献12

同被引文献11

  • 1Yamamoto S,Konishi I, Mandai M, e t al. Expression of vascu- lar endothelial growth factor(VEGF)in epithelial ovarian neo- plasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels[J].Br J Cancer, 1997, 76 (9): 1221 -1227.
  • 2Fujimoto J ,Sakaguchi H, Hirose R, et al. Biologic implications of the expression of vascular endothelial growth factor sub- types in ovarian careinoma[J]. Cancer, 1998, 83 (12) : 2528- 2533.
  • 3Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic signif- icance of vascular endothelial growth factor expression in hu- man ovarian carcinoma[J].Br J Cancer, 2000,83 ( 2 ) : 196-203.
  • 4Koh WP, Yuan J M, Sun CL, et al. Angiotenensin I-converting enzyme(ACE) gene polymorphismad breast cancer risk among Chinese women in Singapore [J]. Cancer Res, 2003, 63 (3): 573-578.
  • 5Won SM, Park YH, Kim HJ, et al. Catechins inhibit angioten- sin II induced vascular smooth muscle cell proliferation via mi- togen-activated protein kinase pathway[J]. Exp Mol Med, 2006,38 (5) : 525-534.
  • 6Suganuma T, Ino K,Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma ceils and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination[J]. Clin Cancer Res,2005,11 (7) : 2 686 -2 694.
  • 7Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angioten- sin- I converting enzyme protect against risk of cancer? [J]. Lancet, 1998,352(9123) : 179-184.
  • 8Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin- Ⅱ type 1 receptor interaction is a major regulator for liver fibrosis devel- opment in rats[J]. Hepatology,2001,34(4 pt 1 ):745-750.
  • 9韩英,林延鹏,刘冬艳,徐文全,崔保栓,李奇巍.培哚普利对小鼠移植性肝癌生长及新生血管生成的抑制作用研究[J].中国煤炭工业医学杂志,2009,12(5):797-799. 被引量:3
  • 10李秋营,韩峰,陈腾,陈超,殷佩浩,陈亚峰,奉典旭.榄香烯对裸鼠胃癌原位移植瘤血管生成的抑制作用[J].肿瘤防治研究,2010,37(3):287-290. 被引量:11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部